InvestorsHub Logo
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

Re: None

Friday, 06/10/2022 7:18:57 AM

Friday, June 10, 2022 7:18:57 AM

Post# of 232488
"Conclusions: The primary endpoint (PDFF) and secondary endpoints (cT1) were met for the 350 mg group and moderate to severe fibro-inflammation by cT1 350 mg subgroup at baseline. The pooled 350 + 700 mg group also had significant reductions in PDFF, cT1 vs placebo. Treatment with leronlimab was well tolerated. These results are supportive of further trials with leronlimab for NASH."

Can you spell "PARTNERSHIP"?

My comments are just my opinions and should NOT be taken as investment advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News